ViroChannel brings together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Switching HIV Regimens: When, Why, and to What
with Dr. Pedro Cahn, Dr. Calvin Cohen, Dr. Graeme Moyle and Dr. Frank J. Palella Jr
As new antiretroviral drugs come on the market, one question that clinicians need to face is when and if they should switch their patients to new cART regimens. In this panel, moderated by Dr. Pedro Cahn, Drs. Frank Pallela, Graeme Moyle, & Calvin Cohen discuss many of the issues around regimen switching.
Topics covered include; which patients should be switched, how to make decisions about initiating a new drug regimen, and the timing of a regimen switch. They also discuss how switching can affect drug adherence, and the importance of educating patients about the pros and cons of any new therapy.
This activity is supported by
an educational grant from:
KEY LEARNING POINTS
- Guidelines for switching cART regimens
- The importance of historical genotypes when considering a regimen switch
- The differences between switching for toxicity and switching for other reasons
- Benefits and disadvantages of single-pill combination therapies
- What it means to simplify a regimen
- Patient-provider education considerations during a regimen switch
Pedro Cahn, MD
Infectious Disease Unit
Juan A Fernandez Hospital
University of Buenos Aires Medical School
Calvin Cohen, MD
Community Research Initiative (CRI)
Boston, Massachusetts, USA
Graeme Moyle, MD
HIV Research Strategy
Chelsea and Westminster Hospital
Frank J. Palella Jr., MD
Potocsnak Family Professor of Medicine
Division of Infectious Diseases
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, USA
You must be logged in to view the complete program
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Pedro Cahn, MD has a financial interest/relationship or affiliation: Merck, GSK, ViiV Healthcare, BMS, Abbott.
Calvin Cohen, MD has a financial interest/relationship or affiliation: Gilead Sciences, Merck, BMS, Janssen Pharmaceuticals, Tobira Therapeutics, ViiV Healthcare.
Graeme Moyle, MD has a financial interest/relationship or affiliation: Gilead Sciences, Merck, BMS, ViiV Healthcare, Astellas Pharma, Ferrer, Bionor.
Frank J. Palella Jr., MD has a financial interest/relationship or affiliation: Gilead Sciences, Johnson & Johnson, BMS, Merck.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.